La cadena de opciones muestra datos clave de las opciones de acciones de Indaptus Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Indaptus Therapeutics..

Indaptus Therapeutics (NASDAQ:INDP) Bolsa, Cadena de Opciones

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

<a href="https://trumpstruth.org/statuses/31622" title="https://trumpstruth.org/statuses/31622">https://trumpstruth.org/statuses/31622</a>

News

Politics

General

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Says On Truth Social ' I want to thank Iran for giving us early notice, which made it possible for no lives to be lost, and nobody to be injured. Perhaps Iran can now proceed to Peace and Harmony in the Region, and I will enthusiastically encourage Israel to do the same.'

Management

BGLC

BioNexus Gene Lab Appoints Chong Set Fui As CFO And Principal Financial Officer, Effective Immediately; Su-Leng Tan Lee Steps Down As Acting CFO

WIIM

PYPL

PayPal shares are trading higher after the company and Fiserv expanded their partnership to advance stablecoin payments.

CRWV

CoreWeave shares are trading lower. The stock may be pulling back after recent strength.

Avis Budget Group shares are trading higher after the company announced the appointment of Daniel Cunha as Chief Financial Officer.

When it comes to investing for income in retirement, many people are looking for safety. That often leads them to consider low-risk options like bonds or Guaranteed Investment Certificates — GICs. But according to <a href="https://www.benzinga.com/personal-finance/management/25/06/45975687/25000-monthly-care-costs-suze-orman-shows-how-long-term-care-insurance-can-protect-your-savings">Suze Orman</a>, personal finance expert and host of the "Women &amp; Money" podcast, not all fixed-income investments offer the same benefits.
In a <a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-i-don-t-trust-my-husband-with-money-what-should-i-do">recent episode</a>, Orman shared why she prefers bonds over GICs — and what investors, especially those approaching or in retirement, should understand before choosing between the two.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">What Is a GIC?</h2>
A <a href="https://www.benzinga.com/money/best-investments-with-guaranteed-returns">GIC</a> is a savings product commonly offered by Canadian banks and financial institutions, which are available in the U.S as well. When you invest in a GIC, you&#8217;re lending the bank your money for a set period — often one to five years. In return, you're promised a guaranteed interest rate and the full return of your original investment when the term ends.
"You&#8217;re essentially lending a bank or a financial institution money for a fixed period of time," Orman explained. The appeal is the safety. GICs are low-risk, and in Canada, they're generally insured up to $100,000.
But that safety comes at a cost.
<h2 class="wp-block-heading">GICs Offer Lower Returns and Less Flexibility</h2>
Orman didn't mince words about the downside. "You generally get a lower return in comparison to a bond," she said. While the return is guaranteed, it's often less than what you could earn with other fixed-income investments.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
Another limitation is liquidity. Most GICs lock in your funds until the end of the term. If you need to access your money early, you may face penalties or restrictions.
"You usually don't get your interest rate until it matures," Orman said. "It&#8217;s not like a bond that if interest rates go down, the value of the bond goes up, that you can easily cash out of."
<h2 class="wp-block-heading">Why Suze Orman Favors Bonds</h2>
Orman prefers bonds for one key reason: flexibility. "You can buy and sell them any time you want," she said. <a href="https://www.benzinga.com/markets/bonds/25/05/45699780/catastrophe-bonds-surge-diversify-your-portfolio-with-alternative-investments">Bonds</a> may also offer higher interest rates than GICs, depending on market conditions and the type of bond.
And there&#8217;s potential for added value. If the value of the bond increases, investors could potentially sell the bond at a profit before maturity.
However, it&#8217;s worth noting that bonds do carry some risk. Their value can fluctuate with interest rate changes, and unlike GICs, they&#8217;re not insured.
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">Choosing What's Right for You</h2>
Ultimately, Orman acknowledged that the right choice depends on your goals. "If you like that your principal is protected, you like the guaranteed return… then just stick with your GICs," she said.
For investors who prioritize security over growth, GICs might still be a solid choice. But for those looking for more flexibility and potentially higher returns, bonds could be worth a closer look.
As always, it's a good idea to speak with a <a href="https://www.benzinga.com/money/best-online-financial-advisors">financial advisor</a> before making changes to your portfolio — especially when planning for retirement income.
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Personal Finance

'You Generally Get A Lower Return With A Guaranteed Investment Certificate In Comparison To A Bond' – Suze Orman Shares Her Preference

Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares plunged over 30% on Monday following reports suggesting the company plans <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46004888/whats-going-on-with-wolfspeed-shares-today">to file for bankruptcy by July 1</a>.
What To Know: According to<a href="https://www.bloomberg.com/news/articles/2025-06-23/wolfspeed-plans-bankruptcy-after-clinching-deal-with-creditors"> Bloomberg</a>, the semiconductor manufacturer reached a restructuring support agreement with key creditors, including Renesas Electronics, to reduce its $6.6 billion debt burden by about $4.6 billion. The deal also aims to cut Wolfspeed's annual interest expenses by 60% and give control of the company to convertible noteholders.
The bankruptcy plan, which has been in the works since at least May, comes as Wolfspeed grapples with stalled government funding and policy shifts under the Trump administration. 
Although the company previously secured a $750 million award from the CHIPS and Science Act to support its production expansion, it has only received partial funding and remains locked in negotiations with federal officials.
Under the proposed restructuring, Wolfspeed shareholders would retain up to 5% ownership of the reorganized company. The deal includes Renesas converting a $2.1 billion deposit into convertible notes, equity and warrants. 
In addition, certain existing noteholders have committed to providing $275 million in new second-lien convertible bonds. Wolfspeed expects to emerge from bankruptcy by the end of the third quarter, pending court approval.
WOLF Price Action: Wolfspeed shares were down 33.2% at 60 cents at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises</a></li>
</ul>
Image via Shutterstock.

Movers

WOLF

What's Going On With Wolfspeed Shares Today?

Moelis shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Overweight and raised its price target from $42 to $68.

Kroger Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) shares are trading higher by 2.39% to $73.69 Monday afternoon. The company last week reported stronger-than-expected first-quarter <a href="https://www.benzinga.com/markets/earnings/25/06/46030486/grocery-giant-kroger-cfo-raises-identical-sales-outlook-but-maintains-caution-due-to-tariff-uncertainty">earnings</a>. The company also received a number of analyst rating <a href="https://www.benzinga.com/quote/KR/analyst-ratings">updates</a> following the earnings print.
What To Know: Adjusted EPS came in at $1.49, topping the $1.46 consensus estimate, while identical sales excluding fuel rose 3.2%, exceeding projections despite ongoing consumer spending headwinds.
Quarterly revenue <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46054132/kroger-posts-q1-beat-analyst-raises-price-target-to-reflect-continued-growth-market-share-gains">totaled</a> $45.12 billion, slightly below expectations, but gross margin improved to 23% from 22% a year ago, aided by the sale of Kroger Specialty Pharmacy and lower supply chain costs.
CFO David Kennerley noted strong momentum, prompting Kroger to raise its full-year identical sales guidance (ex-fuel) from 2%-3% to 2.25%-3.25%, while maintaining conservative profit projections due to macroeconomic uncertainty.
Telsey Advisory Group analyst Joseph Feldman <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46054132/kroger-posts-q1-beat-analyst-raises-price-target-to-reflect-continued-growth-market-share-gains">reiterated</a> an Outperform rating and lifted his price target from $73 to $82, citing the company's strong execution, robust loyalty program, digital enhancements and brand strength. Other analysts also boosted their price targets, with Deutsche Bank, UBS, Guggenheim, and Morgan Stanley all raising their views.
Feldman expects continued growth and market share gains through expanded geography, personalized offerings and paid memberships, positioning Kroger well for 2025 and beyond.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, KR has a 52-week high of $74.11 and a 52-week low of $49.04.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/06/46059497/stocks-rise-oil-tumbles-despite-irans-strikes-on-us-bases-whats-driving-markets-monday">Stocks Rise, Oil Tumbles Despite Iran&#8217;s Strikes On US Bases: What&#8217;s Driving Markets Monday?</a>
<h2 class="wp-block-heading">How To Buy KR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Kroger&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Why Kroger Stock Hit A New 52-Week High Today

Tensions in the Middle East aren't just <a href="https://www.benzinga.com/topic/oil">fueling oil prices</a> &#8211; they're shaking the crypto charts too. As Brent crude flirts with volatility, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) briefly dipped below $90,000 over the weekend before bouncing back Monday, a move that James Toledano, COO of Unity Wallet, says is anything but coincidental.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46050890/bitcoin-ethereum-xrp-dogecoin-weaken-on-iran-israel-tensions-reclaim-105000-or-brace-for-sideways-summer">Bitcoin, Ethereum, XRP, Dogecoin Weaken On Iran-Israel Tensions – Reclaim $105,000 Or Brace For Sideways Summer</a>
<h2 class="wp-block-heading">Crude Awakening: Oil's Growing Pull On Bitcoin</h2>
"Even the whiff of higher oil prices can send the price of a Bitcoin lower," says Toledano. He points to the direct link between rising energy costs and mining profitability &#8211; a vital backbone of the Bitcoin ecosystem. 
"Higher oil prices raise energy costs, directly impacting Bitcoin mining profitability and network dynamics."
That means when oil flares, Bitcoin miners feel the heat. The cost to produce each BTC rises, potentially setting a higher price floor, but also opening the door to more volatility. That dynamic was on full display this weekend as geopolitical risk sent crude prices higher and Bitcoin re-tested recent lows.
<h2 class="wp-block-heading">Risk-Off Reflex &#8211; And A Rapid Recovery</h2>
Beyond mining costs, Bitcoin continues to behave like a risk asset, pulling back when markets turn jittery and investors scramble for liquidity. But the story doesn't end there.
"Bitcoin's relatively mild decline during recent market routs… and its growing correlation with gold signals a maturing narrative," says Toledano. 
Institutional money is staying put, even during macro panic. And just like equities, Bitcoin is starting to bounce back quicker, suggesting it&#8217;s increasingly part of the traditional financial mix.
<h2 class="wp-block-heading">Why It Matters For Traders</h2>
The takeaway? In 2025, oil isn't just fueling your car—it's steering your crypto portfolio. Toledano says oil-informed strategies now offer "higher utility gains" in Bitcoin trading, a nod to the commodity's rising influence in crypto models.
With Middle East tensions still simmering and crude potentially spiking again, don't be surprised if Bitcoin's next move is more Exxon than Ethereum.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46053846/will-bitcoin-hit-new-all-time-highs-after-dip-under-100k-heres-what-new-poll-predicts">Will Bitcoin Hit New All-Time Highs After Dip Under $100K? Here&#8217;s What New Poll Predicts</a></li>
</ul>
Photo: Mc_Cloud on Shutterstock.com

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Markets

Analyst Ratings

Trading Ideas

$BTC

Oil Flares, Bitcoin Wobbles: Why Crude Now Moves The Crypto Needle

-- A milestone in pediatric medicine, general pediatricians are now expected to play a more active role in initiating genetic testing --
-- Earlier use of exome and genome testing delivers better clinical outcomes and reduces costs across the U.S. healthcare system --
-- GeneDx will lead education and adoption efforts to end the diagnostic odyssey --
GeneDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpublications.aap.org%2Faapnews%2Fnews%2F32394%2FClinical-report-outlines-how-why-to-pursue-genetic%3Fautologincheck%3Dredirected&amp;esheet=54281144&amp;newsitemid=20250623706227&amp;lan=en-US&amp;anchor=updated+guidance&amp;index=1&amp;md5=e1c915fc0893b481df5512206e83b504">updated guidance</a> to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because of superior diagnostic yield and higher cost-effectiveness if pursued earlier in the diagnostic process2. For more than 60,000 pediatricians, this milestone marks a turning point in pediatric healthcare, ushering in earlier diagnosis, interventions, and improved outcomes for millions of children.

GeneDx Says AAP Recommends Exome, Genome Sequencing As First-Tier Tests In Most Pediatric ID/GDD Cases

Li Auto, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares are trading higher Monday after the company reportedly filed for its Li i6 SUV model, with a launch <a href="https://www.benzinga.com/quote/LI">expected in September</a>.
What To Know: The Li i6, a five-seat all-electric SUV, has been included in China's latest vehicle catalog of vehicles pending approval, signaling potential regulatory clearance ahead of its anticipated market debut, according to <a href="https://cnevpost.com/2025/06/20/li-auto-files-for-i6-launch-sept/">CnEVPost</a>. 
China&#8217;s Ministry of Industry and Information Technology released the catalog, which is considered one of the last regulatory procedures before a vehicle can be deemed ready for sale in the country. The company reportedly plans to launch the model, which is its second SUV model, in September.
Li Auto said the i6 will serve as a mainstream purchasing option and targets buyers considering luxury mid-size SUVs such as the Mercedes-Benz GLC, BMW X3 and Audi Q5. The vehicle is expected to be equipped with Li Auto's AD Max intelligent driving system and powered by an 800 V platform.
<h3 class="wp-block-heading">How To Buy LI Stock</h3>
By now you're likely curious about how to participate in the market for Li Auto &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
LI Price Action: At the time of publication, Li Auto shares were up 7.84% at $28.05, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiKprHjgIiOAxUTjYkEHexJEcUQFnoECBAQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46057391/is-a-20-decline-in-your-portfolio-a-loss-does-it-always-make-sense-to-think-so">Is A 20% Decline In Your Portfolio A Loss? Does It Always Make Sense to Think So?</a></li>
</ul>
Image: Robert Way/Shutterstock.

Global

Li Auto Stock Is Trading Higher Monday: What's Going On?

<a href="https://www.youtube.com/watch?v=gsr6tnlq1k0" title="https://www.youtube.com/watch?v=gsr6tnlq1k0">https://www.youtube.com/watch?v=gsr6tnlq1k0</a>

TMUS

T-Mobile Executive Says To Launch Data On T-Satellite On October 1; Says Over 1.8 Million Customers Signed Up For T-satellite Network

JBLU

Shares of airline stocks are trading higher, reversing from earlier weakness as oil prices fall. Investors may be assessing Iran's attack on an American base in Qatar and the impact on travel demand.

Kroger shares are trading higher after multiple firms raised their respective price targets on the stock.

Estee Lauder shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $71 to $95.

Reuters Citing Iran's Semi-Official Tasnim News Agency

Iran Parliament Committee Approved General Plan To Suspend Cooperation With The IAEA

Macro Economic Events

Market Summary

Economics

TSLA

Benzinga Market Summary: S&P Rises And Oil Falls As Investors Assess Iran's Attack On US Base In Qatar, Tesla Rises On Robotaxi Rollout

Financial giants have made a conspicuous bearish move on MongoDB. Our analysis of options history for MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $1,955,208, and 4 were calls, valued at $142,292.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $240.0 for MongoDB over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for MongoDB's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MongoDB's whale activity within a strike price range from $160.0 to $240.0 in the last 30 days. 
<h3>MongoDB 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750705610_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.85</td>
<td>$10.65</td>
<td>$10.84</td>
<td>$180.00</td>
<td>$1.6M</td>
<td>442</td>
<td>1.5K</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$25.6</td>
<td>$24.55</td>
<td>$25.07</td>
<td>$190.00</td>
<td>$75.4K</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.35</td>
<td>$11.3</td>
<td>$11.3</td>
<td>$160.00</td>
<td>$61.0K</td>
<td>1.0K</td>
<td>55</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$57.1</td>
<td>$52.15</td>
<td>$54.35</td>
<td>$240.00</td>
<td>$59.7K</td>
<td>215</td>
<td>11</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$38.25</td>
<td>$38.15</td>
<td>$38.15</td>
<td>$240.00</td>
<td>$57.2K</td>
<td>69</td>
<td>15</td>
</tr>
</tbody>
</table>

<h3>About MongoDB</h3>
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
In light of the recent options history for MongoDB, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is MongoDB Standing Right Now?</h3>
<ul>
<li>With a trading volume of 973,140, the price of MDB is up by 0.57%, reaching $202.65.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About MongoDB</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $265.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on MongoDB, which currently sits at a price target of $270. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on MongoDB with a target price of $230. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on MongoDB with a target price of $290. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on MongoDB, which currently sits at a price target of $260. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on MongoDB, which currently sits at a price target of $275. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for MongoDB, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on MDB Options

Financial giants have made a conspicuous bearish move on Netflix. Our analysis of options history for Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) revealed 98 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 33 were puts, with a value of $2,212,866, and 65 were calls, valued at $7,813,270.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $2440.0 for Netflix, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Netflix stands at 451.81, with a total volume reaching 4,986.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Netflix, situated within the strike price corridor from $10.0 to $2440.0, throughout the last 30 days.
<h3>Netflix 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750705605_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$786.0</td>
<td>$776.05</td>
<td>$780.0</td>
<td>$500.00</td>
<td>$702.0K</td>
<td>53</td>
<td align="right">15</td>
</tr>
<tr>
<td>NFLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$139.6</td>
<td>$136.5</td>
<td>$137.29</td>
<td>$1280.00</td>
<td>$683.5K</td>
<td>59</td>
<td align="right">50</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$1235.85</td>
<td>$1229.4</td>
<td>$1231.66</td>
<td>$10.00</td>
<td>$369.4K</td>
<td>6.0K</td>
<td align="right">6</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$780.0</td>
<td>$776.0</td>
<td>$780.0</td>
<td>$500.00</td>
<td>$234.0K</td>
<td>53</td>
<td align="right">3</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$462.55</td>
<td>$460.0</td>
<td>$460.0</td>
<td>$1000.00</td>
<td>$230.0K</td>
<td>79</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Netflix</h3>
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
In light of the recent options history for Netflix, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Netflix</h3>
<ul>
<li>With a volume of 1,545,837, the price of NFLX is up 1.37% at $1248.26. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>What Analysts Are Saying About Netflix</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1445.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Netflix with a target price of $1425. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Netflix, maintaining a target price of $1500. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1450. 
&#x2A; Consistent in their evaluation, an analyst from Pivotal Research keeps a Buy rating on Netflix with a target price of $1600. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Netflix, which currently sits at a price target of $1250. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Netflix with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

NFLX

Unpacking the Latest Options Trading Trends in Netflix

Legal

Press Releases

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Earnings

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Health Care

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

INDP

Apollomics Inc. - Class A Ordinary Shares

Apollomics

180 Life Sciences

Azitra

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

Maxim Group

HC Wainwright & Co.

Screenshot 2025-05-27 at 5.38.59 PM

Biotech

Reiteration

Indaptus Therapeutics Q1 Update: Company Advances Decoy20 Immunotherapy To Fight Cancer, Maxim Group Analyst Reiterates Buy Rating

Screenshot 2025-04-21 at 5.37.26 PM

Bacteria: The Surprising Tool In The Fight Against Cancer – And How Indaptus Is Taking It Further

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL